In an effort to explore and identify functional domains within the structural proteins of human immunodeficiency virus type 1 (HIV-1), a number of laboratories have produced monoclonal antibodies (MAbs) against HIV-1. While most MAbs have been of rodent origin (3, 7, 10, 12, 18, 21, 26, 36, 38) , a number of laboratories have had success in generating human MAbs (huMAbs) against HIV-1 envelope (1, 8, 14-16, 27, 37, 42) and core (11, 14, 16) antigens. These huMAbs offer certain advantages over more traditional murine MAbs (muMAbs), since huMAbs can be used therapeutically without inducing antihuman immunoglobulins, can interact with certain species-specific human proteins such as proteins of the alternative complement pathway, and represent epitopes to which individual patients have responded immunologically during a natural HIV infection.
Several antienvelope MAbs possessing biological activity have been described. These activities include the ability to neutralize HIV-1 infection in vitro and the ability to lyse HIV-1-infected cells in vitro via antibody-dependent cellmediated cytotoxicity (ADCC). For example, several typespecific neutralizing MAbs to the V3 loop of HIV-1 have been reported (3, 15, 18, 21) . This activity was mediated by eight different muMAbs (3, 18, 21) and two huMAbs (15) . One report describes the isolation of a neutralizing muMAb directed against amino acids (AA) 728 to 745 of the HIV-1 transmembrane glycoprotein gp4l (7) . The importance of this peptide is supported by the production of weakly neutralizing polyclonal antibodies in rabbits following immunization with a synthetic peptide homologous to AA 728 to 745 (4) . An additional seven muMAbs mapping to AA 423 to 437 of the HIV-1 envelope gpl20 glycoprotein were shown to * Corresponding author.
have group-specific neutralizing activity (3) . Several antienvelope MAbs have been shown to mediate ADCC in vitro. One of these was an muMAb directed against the V3 loop (3), while several huMAbs that bind to gp4l could also mediate ADCC (41) . One huMAb mediating ADCC was shown to bind to AA 644 to 663 of the HIV-1 transmembrane glycoprotein gp4l (41) , while another bound to AA 579 to 604 of gp4l (41) .
Previous reports had demonstrated that complement-mediated antibody-dependent enhancement (C'-ADE) of HIV-1 infection required antibody to HIV-1 envelope glycoproteins (32) and proteins of the alternative complement pathway (31) . Recently, it was shown that several huMAbs against two immunodominant regions within the HIV-1 gp4l transmembrane glycoprotein could mediate C'-ADE of HIV-1 infection in vitro (28) . In the study reported here, it is demonstrated that enhancing huMAbs bind to two distinct domains in the HIV-1 transmembrane gp4l. The first domain was previously demonstrated to bind enhancing antibodies (29) Disulfide bond reduction. The ELISA plates were coated with antigen (peptide AA579-613) as described above at a concentration of 2 ,ug per well. Wells were then treated for 1 h at 37°C with 100 RI of dithiothreitol (500 pmol per well) in 0.01 carbonate buffer at pH 9.6. This and all subsequent steps were performed under a nitrogen atmosphere. Next, dithiothreitol was removed, and the wells were treated with 100 ,ul of iodoacetic acid (500 pmol per well) in 0.01 M carbonate buffer, pH 9.6, for 1 h at 37°C. Then, all wells were washed six times with 200 ,l of 2 mM acetate buffer at pH 4.5. Wells were then blocked with 1% BSA in PBS, and ELISA was performed as described above except that all steps were done under N2.
Assay for blockade of C'-ADE. In 96-well microdilution plates, twofold dilutions of each peptide were made in growth medium supplemented with huMAb 50-69 (80 ng/ml), huMAb 120-16 (90 ng/ml), or serum number 200 (1:500 dilution) and 1:20 human complement. HIV-1 was added and incubated at 37°C for 1 h, and then 2 x 105 MT-2 cells were added to each well. The cells were incubated for 2.5 days at 37°C in sealed modular incubators containing 5% CO2 and 95% air. Cells were harvested for determination of cytopathic effect as described before (23) 
RESULTS
Enhancing huMAbs. Previously, it had been demonstrated that huMAb 120-16 enhanced HIV-1 infection in vitro from concentrations of 12.5 ,ug/ml to 7 ng/ml. As illustrated in Table 1 , three new huMAbs have recently been identified which enhance HIV-1 infection in vitro, huMAbs 50-69, 240-D, and 246-D. Two of the three are of the IgGl kappa chain immunoglobulin subclass, while 50-69 is of the IgG2 kappa subclass. These huMAbs enhanced HIV-1 infection in vitro to minimum concentrations of 12 to 22 ng/ml. Enhancing huMAbs were identified in an in vitro cytopathic effectbased assay of HIV-1 infectivity described previously (30) .
Two of the huMAbs, 120-16 and 50-69, were tested in in vitro assays for the ability to synergize and thereby produce greater C'-ADE than either huMAb alone. These results are shown in Fig. 1 . Although both 120-16 and 50-69 enhanced HIV-1 infection alone, they were much more effective together. Furthermore, when mixed dose-effect analyses were done by the method of Chou and Talalay (6), these antibodies were synergistic. Synergy is defined by combination indices of less than 1. The combination indices for 120-16 plus 50-69 were 0.2 to 0.002 at all huMAb concentrations tested. For these analyses, R = 0.9941, m = 1.021, and Dm = 39.7 ng/ml, where R is the linear regression correlation coefficient, m is the slope, and Dm is the median-effect dose. For tissue culture-derived data, R should be greater than 0.95 for the Chou and Talalay analyses to be valid; m > 1 denotes a sigmoidal curve. These results suggest that the two antibodies recognize different, noncompeting epitopes of HIV-1.
Peptide mapping of enhancing domains. With standard ELISA methods, huMAbs were screened undiluted at concentrations ranging from 9 to 45 ,ug/ml against several peptides homologous to the HIV-1 41-kDa transmembrane glycoprotein. As shown in Synthetic peptides compete with HIV-1 for biological activity mediated by huMAbs. To confirm that the peptides recognized by the enhancing huMAbs, as determined by ELISA, were biologically active, enhancing huMAbs 50-69 and 120-16 were first incubated with peptide before the addition of HIV-1. As illustrated in Fig. 2 , C'-ADE mediated by 50-69 was completely inhibited by the peptide AA579-613. Peptides AA488-510, AA597-613, and AA644-663 were completely incapable of inhibiting this enhancing activity. In similar experiments, peptide AA644-663 could inhibit the interaction between huMAb 120-16 and HIV-1, as illustrated by 26% inhibition of C'-ADE (Table 5) ; peptide AA579-613 could not inhibit C'-ADE mediated by huMAb 120-16 (data not shown). Inhibition of C'-ADE denotes an increase in viable cells compared with the number in the C'-ADE control infection; i.e., protection from enhancing antibodies. None of these peptides had any effect on HIV-1 infection in the absence of C'-ADE (data not shown).
Synthetic peptides inhibit C'-ADE mediated by human anti-HIV-1 polyclonal serum. The ability of peptides AA579-613 and AA644-663 to block C'-ADE mediated by HIV-1 antibody-positive serum was also tested. described, the peptide AA579-613 could block C'-ADE mediated by a pooled HIV-1 immunoglobulin fraction (33) (Fig. 3) . As illustrated in Fig. 3 , peptide AA579-613 could also block C'-ADE mediated by serum from an HIV-1 antibody-positive individual. Inhibition in this study was approximately 30% for a 1:400 dilution of anti-HIV-1 serum 200 (a potent HIV-1 infection-enhancing serum); furthermore, this peptide could inhibit HIV-1 infection to a minimum concentration of 125 ng/ml. The AA644-663 peptide could also partially block enhanced HIV-1 infection mediated by the immune globulin but had no effect on the HIV-1-positive serum (Table 5 ). This peptide was less effective at blocking C'-ADE than was the AA579-613 peptide.
Homology between HIV-1, HIV-2, and SIV isolates. Previous results had demonstrated that enhancing huMAbs were directed against immunodominant regions of gp4l when competition studies with human HIV-1 antibody-positive sera were performed (28) . Since the four enhancing huMAbs were mapped to two domains, sequence comparisons be- tween HIV-1, HIV-2, and SIV isolates were performed. As illustrated in Fig. 4 , both domains are highly conserved among the isolates listed in the Los Alamos sequence directory (25) .
DISCUSSION
Data from experiments on C'-ADE with huMAbs demonstrate that two immunogenic domains in the HIV-1 transmembrane glycoprotein gp4l are important for in vitro enhancement of HIV-1 infection. The first of these two domains, AA 579 to 613, binds five enhancing huMAb (29; this study). This peptide is strongly reactive with HIV antibody-positive serum and has been demonstrated to be the primary immunodominant domain of gp4l (5, 13, 19, 34) . A portion of this domain, AA 579 to 586, has been demonstrated to be a cytotoxic T-cell epitope (34) . Furthermore, at least one of the enhancing huMAbs which recognizes this domain, 50-69, has also been shown to mediate ADCC (41) .
The second domain, AA 644 to 663, has been identified as an immunodominant domain (19) and has been shown to bind antibodies that mediate ADCC in vitro (41) .
The ability of these two domains to stimulate the in vivo formation of antibodies that confer C'-ADE of HIV-1 infection was demonstrated in several ways. First, huMAbs which mediate C'-ADE were directed toward these two domains. Second, the peptides blocked C'-ADE mediated by both polyclonal human anti-HIV serum and the enhancing huMAbs. Third, the primary requirement for an antibody to mediate enhancement was the ability of the huMAb to bind to one of the two immunogenic domains; neither immunoglobulin subclass nor ability to activate complement was a major factor (28, 29; this study), although these may play a minor role. Finally, the ability of huMAbs 120-16 and 50-69 to synergize in vitro and to enhance HIV-1 infection to a level approaching that found in polyclonal anti-HIV serum (Fig. 1 ) makes it appear that there are at most a few enhancing epitopes in the HIV-1 envelope glycoproteins which can stimulate the production of enhancing antibodies. The magnitude of this enhancement is illustrated in Fig. 1 and in references 28, 29, and 30.
The peptide from the second domain, AA644-663, was much less capable of competing with HIV-1 than was the peptide from the primary immunodominant domain, AA579-613. This was evidenced by the weak inhibition of C'-ADE mediated by huMAb 120-16 by peptide AA644-663 (Table 5) compared with the complete inhibition of C'-ADE mediated by huMAb 50-69 (Fig. 2) by peptide AA579-613. Reasonable explanations include the possibility that AA644-663 is a much less antigenic domain than is AA579-613, a hypothesis supported by quantitation of antibody in patient sera to these two epitopes (41a). It is also possible that antibodies to this domain bind more effectively to native gp4l than to the synthetic peptide. This is supported by the finding that the synthetic peptide blocked C'-ADE mediated by huMAb 120-16 by only 30% and barely blocked C'-ADE mediated by human anti-HIV serum.
The two domains described herein are highly conserved between HIV-1, HIV-2, and SIV isolates (Fig. 4) . Although both domains have been identified as immunogenic (5, 13, 19, 34) , there are relatively few nonconservative amino acid substitutions between these three lentiviruses. Considering the high degree of mutability inherent in the HIV-1 glycoproteins and the selective pressure that should occur in vivo, this would suggest that these domains play an important role in the pathogenesis of both HIV and SIV infections. In vitro, human polyclonal antibodies against HIV-2 and monkey polyclonal antibodies against SIV both enhance HIV-1 infection (unpublished data). Therefore, the conserved nature of this region is mirrored by the immune response to these domains. One area of relatively high variability exists in the disulfide loop between AA 598 and 604. The disulfide loop itself is present in all isolates of HIV and SIV. The amino acids in the loop, however, are completely different. Thus, the architecture of a seven-amino-acid loop may be more important than the actual amino acid sequence of the loop. Alternatively, the lack of identity between amino acids within the loop may be important for the lack of crossreactivity between the enhancing anti-HIV huMAbs and SIV (data not shown).
Although the in vitro mechanism of C'-ADE has been described (30, 33) and has been shown to require cells bearing both CD4 and complement receptor type 2 (30, 33) , the in vivo relevance of enhancing antibodies remains to be determined. Nevertheless, there is a growing body of evidence to suggest that enhancing antibodies are important in the pathogenesis of lentivirus infection. In the SIV model of HIV-1 infection, the levels of enhancing antibodies rise as animals progress toward death, with peak enhancing antibody titers observed immediately prior to death (22) . For HIV, it has been demonstrated by using Fc receptor-mediated ADE that patients' antibodies initially can enhance but not neutralize their own viral isolate. Furthermore, later in infection, when antibodies that neutralize a viral isolate from a previous timepoint are detectable, newly isolated virus is subject only to enhancement, not to neutralization (17) .
These results suggest that selective pressures are present which favor the maintenance of an enhancing serotype.
In vaccine trials, there is additional evidence of enhancement of both HIV-1 infection and SIV infection in vivo.
Despite successful immunizations of rhesus macaques with whole, inactivated SIV (9, 24, 39) , there have been several noteworthy failures. For example, macaques immunized with inactivated SIV and subsequently mucosally challenged with SIV were not protected and may have shown increased illness (39) . Macaques which were immunized with a vaccinia virus-SIV envelope recombinant virus and were subsequently boosted with whole inactivated SIV, thus developing high humoral responses to the SIV envelope, were not protected from SIV challenge, although the same whole inactivated SIV had protected other animals (9) . Finally, in a recently published study in which recombinant gpl20 protected two chimpanzees from subsequent challenge with HIV-1, it was shown that two additional chimpanzees which had received recombinant gpl60 were not protected (2) . This gpl60 preparation contained the two domains to which enhancing antibodies bind. In fact, there was some evidence that HIV-1 infection was enhanced, since humoral responses against the HIV-1 p24 core antigen were apparent much earlier in the gpl60-immunized animals than in the control animal (2) .
Although there is still much debate as to the importance of ADE of HIV-1 infection in HIV-1 pathogenesis, there is some evidence that ADE may be important. The identification and mapping of enhancing huMAbs provide tools which can be used to determine the in vivo importance of C'-ADE. Additional studies should be performed to determine whether anti-SIV mAbs (20) can enhance SIV infection in vitro. If so, epitopes which bind SIV-enhancing antibodies could be mapped directly. Future studies should involve the immunization of macaques with the SIV equivalent of both domains to which enhancing antibodies bind and the subsequent challenge of immunized and control macaques with the same isolate of SIV. Only these types of experiments, in which animals are challenged in the presence of "pure" enhancement, will allow the determination of whether enhancement is important in vivo. Nevertheless, the identification of two domains which bind enhancing antibodies in gp4l should alert vaccine developers to the possible benefits of deleting such domains from future vaccine candidates.
